...
首页> 外文期刊>Circulation journal >Endothelial Progenitor Cells Predict Long-Term Prognosis in Patients With Stable Angina Treated With Percutaneous Coronary Intervention – Five-Year Follow-up of the PROCREATION Study –
【24h】

Endothelial Progenitor Cells Predict Long-Term Prognosis in Patients With Stable Angina Treated With Percutaneous Coronary Intervention – Five-Year Follow-up of the PROCREATION Study –

机译:血管内皮祖细胞可预测经皮冠状动脉介入治疗稳定型心绞痛的患者的长期预后–随访5年的PROCREATION研究–

获取原文

摘要

Background: ?The association between endothelial progenitor cells (EPCs) at the time of percutaneous coronary intervention (PCI) and the subsequent long-term clinical outcome remains undefined. To address this issue, a pre-specified analysis of the PROgenitor Cells role in Restenosis and progression of coronary ATherosclerosis after percutaneous coronary intervention (PROCREATION) study was done. Methods and Results: ?A total of 155 patients with stable angina treated with PCI had flow cytometry before PCI. Patients had a 5-year follow-up. Primary outcome was the composite of major adverse cardiac or cerebrovascular events (MACCE), that is, death, stroke, myocardial infarction, and revascularization. During follow-up, MACCE occurred in 65 of 155 patients (42%). There were no significant differences in clinical and angiographic variables between patients with or without MACCE, apart from a different extent of coronary atherosclerosis. The incidence of MACCE increased significantly over tertiles of CD34+/KDR+/CD45– cells and CD133+/KDR+/CD45– cells, with rates of 25%, 39%, and 69% (P=0.0001), and 26%, 44%, and 59% (P=0.003), respectively. On multivariate analysis it was estimated that the increase in CD34+/KDR+/CD45– cells was associated with a 35% higher risk for MACCE (hazard ratio [HR], 1.75; 95% confidence interval [CI]: 1.07–1.99; P=0.001), and the increase in CD133+/KDR+/CD45– cells was associated with a 25% higher risk for MACCE (HR, 1.35; 95% CI: 1.01–1.74; P=0.03). Conclusions: ?Assessment of subpopulations of circulating EPCs in patients with stable angina treated with PCI can improve characterization of long-term prognosis (ClinicalTrials.gov: NCT01575431).??(Circ J?2013; 77: 1728–1735)
机译:背景:?经皮冠状动脉介入治疗(PCI)时内皮祖细胞(EPC)与随后的长期临床结局之间的关联仍不确定。为了解决这个问题,对经皮冠状动脉介入治疗(PROCREATION)后的祖细胞在再狭窄和冠状动脉粥样硬化进展中的作用进行了预先指定的分析。方法和结果:总共155例接受PCI治疗的稳定型心绞痛患者在PCI前进行了流式细胞术。患者进行了5年的随访。主要结局是主要不良心脏或脑血管事件(MACCE)的综合,即死亡,中风,心肌梗塞和血运重建。在随访期间,155例患者中有65例发生了MACCE(42%)。有或没有MACCE的患者,除了冠状动脉粥样硬化程度不同外,在临床和血管造影方面无显着差异。与CD34 + / KDR + / CD45–细胞和CD133 + / KDR + / CD45–细胞的三分位数相比,MACCE的发生率显着增加,发生率分别为25%,39%和69%(P = 0.0001),以及26%,44%,和59%(P = 0.003)。在多变量分析中,估计CD34 + / KDR + / CD45–细胞的增加与MACCE风险增加35%相关(危险比[HR]为1.75; 95%置信区间[CI]:1.07-1.99; P = 0.001),而CD133 + / KDR + / CD45–细胞的增加与MACCE风险高25%相关(HR,1.35; 95%CI:1.01-1.74; P = 0.03)。结论:?对稳定的心绞痛患者行循环EPC的亚群进行PCI治疗可以改善长期预后的特征(ClinicalTrials.gov:NCT01575431)。(Circ J?2013; 77:1728-1735)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号